News & events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

OncoArendi Therapeutics Announces Selection of Its Second Clinical Development Candidate: OATD-02 For the Treatment of Multiple Cancers

21 June 2017

OncoArendi raises 4.5 mln USD (18 million PLN) in an extension of Series A financing round

8 March 2017

OncoArendi receives the President’s Economic Award as the best Polish R&D Company in 2016

17 November 2016

OncoArendi Therapeutics has entered into a global license agreement with Yale University

10 February 2015

Michał Sołowow invested in OncoArendi Therapeutics Sp. z o.o.

19 January 2015

Oncoarendi Therapeutics won over 25.5 million zloty

23 December 2014

Events & Presentations

R&D Day Presentation, 07.12.2022

7 December 2022

Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches – February 19-23, 2020 | Victoria, BC, Canada

27 February 2020

EFMC-ASMC’19 – September 1-5, 2019 | Athens, Greece

11 September 2019

ACS National Meeting & Expo – August 25 – 29, 2019 | San Diego, CA

4 September 2019

ATS- International Conference – Dallas, 17-22.05.2019

22 May 2019

EFMC – YMCS – Young Medicinal Chemist Symposium – Ljubljana 02-06.09.2018

17 September 2018